We're Out of TimeThe Future of Addiction Treatment Starts Here: GLP-1s Explained With Dr. Ken Spielvogel

Why off-label isn’t scary

17:18–18:05 · 47s

The pair debate slow industry adoption; Dr. Spielvogel defends off-label use with everyday examples like baby aspirin and Indocin, pushing back on hesitation.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.